NR nicotinamide riboside, NMN β-nicotinamide mononucleotide, and NADH reduced nicotinamide adenine dinucleotide all belong to NAD+ precursors or related molecules. They all participate in the synthesis and cycling of NAD+ in the body, and are therefore considered important members of the "anti-aging nutrient family." So, among these options, which is more suitable as an ideal NAD+ supplement? Generally speaking, a high-quality supplement should have high bioavailability, a good safety profile, low toxicity, and sufficient clinical research support. Based on these criteria, it is necessary to conduct a systematic comparative analysis of different components.
NR (nicotinamide riboside)
NR, or nicotinamide riboside, is an indirect precursor of NAD+. It requires multiple conversion steps in the body to form active NAD+. The absorption and conversion efficiency of NR is limited by various factors. Therefore, its bioavailability is lower than that of NMN or NADH. Specifically, there are two main pathways for the conversion of NR to NAD+. The first is that NR is first phosphorylated to generate NMN, which is then further converted to NAD+. The second is through a complex five-step reaction: NR → nicotinamide (NAM) → NAM mononucleotide (NAMN) → NAAD+ → NAD+. Both pathways are relatively convoluted. Furthermore, their conversion rate is limited by key rate-limiting enzymes such as NPK1, NPK2, and NAMPT.
More importantly, animal and human studies show that NR is highly unstable in the body and readily and rapidly degrades into conventional vitamin B3, namely nicotinamide (NAM). After oral administration, most of the nicotinamide riboside chloride powder is broken down into NAM, resulting in its actual absorption efficiency being far lower than that of other NAD+ precursors. This is only about one-tenth to one-hundredth of that of NMN or NADH. Therefore, despite NR's potential as a precursor to NAD+, its actual bioavailability remains significantly limited. This necessitates sophisticated formulation design and transformation strategies to achieve better efficacy.
1. Clinical trials of NR
Although there are more clinical trials of nicotinamide nucleoside (NR) than nicotinamide mononucleotide (NMN), its actual efficacy is slightly inferior. As early as 2004, related studies showed that NR could alleviate age-related functional decline in various mouse models, and animal application research has a history of 20 years. However, the actual application of NR in humans started much later, with only about 12 years of use since 2012.
To date, 66 clinical trials related to NR have been published, of which only 8 have been completed and have results. Most studies have found that NR can effectively increase NAD+ levels in the blood, but its effect on improving NAD+ in muscle tissue is limited. Positive results in animal experiments regarding energy metabolism, insulin sensitivity, and cardiopulmonary function have rarely been replicated in human trials.
Overall, NR has limited effects on NAD+ physiological regulation. Although it can directly supplement NAD+, its distribution and timing of action may not fully match actual needs, and its overall health benefits remain uncertain, requiring more long-term, large-scale human studies for verification.
2. Side effects:
Chemically synthesized NR poses potential safety risks. Because NR cannot be naturally biosynthesized, chlorine must be added during production to maintain stability, making it a non-natural product. Some studies and consumer feedback indicate that oral NR may cause vasodilation, skin flushing, and even affect muscle function and motor ability. Therefore, its safety requires further evaluation.
NMN (β-nicotinamide mononucleotide)
NMN (β-nicotinamide mononucleotide) is a direct precursor of NAD. After entering the human body, it is converted to NAD⁺ by the rate-limiting enzyme NMNAT. This conversion process requires energy (ATP) and is limited by the activity of the rate-limiting enzyme. Therefore, the conversion efficiency is not unlimited. Compared to other NAD precursors, such as NR (nicotinamide nucleoside) or NADH, NMN exhibits a unique advantage in conversion rate. Although its conversion rate is limited due to the rate-limiting enzyme, it is not restricted by multiple enzymes like NR, thus its overall conversion efficiency is relatively higher. To further improve conversion efficiency, scientists have tried various strategies. These include chemically modifying NMN, such as adding hydrogen (H), to overcome the bottleneck of the rate-limiting enzyme.
1. Clinical trials of NMN
From clinical studies, NMN outperforms NR. In 2013, Professor David Sinclair of Harvard Medical School first discovered the anti-aging effects of NMN, and related research has been ongoing for over a decade since then. The application of NMN in humans began about eight years ago, and currently, there are 30 registered clinical trials worldwide. Research results show that oral NMN supplementation can significantly increase NAD⁺ levels in the body, thereby improving various age-related physiological problems, including oxidative stress, DNA damage, neurodegenerative diseases, and neurodegeneration. Furthermore, multiple clinical trials have verified the oral safety of NMN, with no serious adverse reactions found, demonstrating its potential feasibility as a health supplement and intervention for aging.
2. Regulatory recognition of NMN is also constantly evolving.
In November 2022, the US FDA announced that NMN is no longer considered a general dietary supplement, but rather a drug or drug ingredient requiring FDA approval. This policy change means that the use and promotion of NMN in the US market will be subject to stricter regulations, while also reflecting its potential value in the fields of medical and nutritional intervention. In summary, NMN, as a direct precursor to NAD⁺, has garnered significant attention in anti-aging and health management due to its unique biotransformation properties, clinical research data, and safety profile.
3. Side Effects
No obvious side effects were found. NMN is a naturally occurring substance in the human body, and moderate intake usually does not cause side effects. However, this requires that the NMN supplements be produced under strict quality control to ensure there are no safety hazards. People who directly consume raw powder often lack understanding of the formulation process, which poses a significant safety risk. Furthermore, NMN is a chiral compound. If it is not purified, it may also present potential safety issues. Therefore, the industry is increasingly emphasizing the safety of NMN production and use, stressing the need for standardized processes and purification procedures to ensure product reliability and safe intake.
NADH (reduced nicotinamide adenine dinucleotide)
NADH is the reduced form of NAD+. After entering the body, it can be directly broken down into NAD+ and hydrogen (H), releasing energy in the process. This characteristic gives it a unique advantage within the NAD+ family. In terms of absorption and conversion rate, NADH is not limited by a single enzyme, making it the most efficient member of the family. The US FDA has explicitly stated that NADH is extremely unstable. This instability is both its advantage and a bottleneck in its development. As a dietary supplement that has been a bestseller in Europe and America for 30 years, NADH's success or failure stems from this.
1. Instability
Because of its instability, it decomposes rapidly after entering the body. Unlike NR, it does not undergo multiple conversions, nor is it affected by rate-limiting enzymes or has an energy-consuming synthesis reaction like NMN. Therefore, its conversion rate far exceeds that of both. The NAD+, hydrogen, and energy produced during its decomposition work synergistically to further enhance its anti-aging effects. However, this instability also places extremely high demands on the product manufacturing process, resulting in very few NADH products on the market that truly guarantee their stability.
2. Clinical Data Performance:
18 clinical trials have been completed. NADH was discovered in 1903 by a Nobel laureate and applied to basic biological research. It wasn't until 1987 that Professor Walther Birkmayer, the discoverer of Parkinson's disease medication, applied NADH to Parkinson's patients with remarkable results. Since then, research on NADH in the field of health and medicine has increased significantly, particularly its powerful antioxidant and anti-aging effects. Research on the application of NADH began in 1987, and its human use has a history of 37 years. Currently, there are 19 registered clinical trials worldwide, 18 of which have been completed.
3. Side Effects
NADH has undergone animal toxicity testing in rats and dogs. Even at high concentrations, NADH has not shown any toxicity or side effects. NADH is also the only natural product in the NAD+ family to be approved by Health Canada, receiving NPN certification.
Over 100,000 people worldwide have taken NADH dietary supplements. According to data from the FDA Adverse Event Reporting System and the CFSAN Adverse Event Reporting System (CAERS), there have never been any reports of adverse events caused by oral NADH.
Therefore, NADH is also recognized as a legitimate natural nutritional supplement by Drugbank, the world's largest and most comprehensive database of drugs and drug targets.
Conclusion
NR, NMN, and NADH each play distinct roles as NAD⁺-related compounds, but their practical value differs when evaluated by bioavailability, safety, and clinical support. NR shows limited efficiency due to complex conversion pathways and instability. NMN offers improved conversion and growing clinical validation, though it remains constrained by enzymatic limits and evolving regulatory status. In contrast, NADH demonstrates superior absorption efficiency and direct participation in NAD⁺ cycling, supported by long-term use and strong safety data. Overall, while NMN and NR remain relevant, NADH appears to be the most efficient and reliable option as an NAD⁺ supplement. Guanjie Biotech is an NAD supplier. We supply bulk NR nicotinamide riboside, NMN β-nicotinamide mononucleotide, and NADH reduced nicotinamide adenine dinucleotide at high quality and competitive prices. Welcome to enquire with us at info@gybiotech.com.
References
[1] Yoshino J, Baur J A, Imai S. NAD+ intermediates: the biology and therapeutic potential of NMN and NR[J]. Cell metabolism, 2018, 27(3): 513-528.
[2] Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans[J]. Cell, 2004, 117(4): 495-502.
[3] Conze D, Brenner C, Kruger C L. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults[J]. Scientific Reports, 2019, 9(1): 1-13.
[4] Gomes A P, Price N L, Ling A J Y, et al. Declining NAD+ induces a pseudohypoxic state, disrupting nuclear-mitochondrial communication during aging[J]. Cell, 2013, 155(7): 1624-1638.
[5] Lu H, Burns D, Garnier P, et al. P2X7 receptors mediate NADH transport across the plasma membranes of astrocytes[J]. Biochemical and biophysical research communications, 2007, 362(4): 946-950.
